Development of 11C-Tucatinib as a potential HER2-targeting PET radiotracer

被引：0
|
作者：
Muller, Marius [1 ]
Battisti, Umberto [1 ]
Shalgunov, Vladimir [1 ]
Jorgensen, Jesper [1 ]
Hvass, Lars [1 ]
Kramer, Vasko [2 ]
Kjaer, Andreas [1 ]
Herth, Matthias [1 ]
机构：
[1] Univ Copenhagen, Copenhagen, Denmark
[2] Positronpharma SA, Santiago, Chile
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2022年 / 108卷
关键词：
BREAST-CANCER; TRASTUZUMAB; METASTASES; ONCOGENE;
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P-287
引用
收藏
页码：S206 / S206
页数：1
相关论文
共 50 条
  • [41] Developing Her2-targeting ligands using quantitative super-resolution microscopy.
    Golfetto, O.
    Jorand, R.
    Biswas, S.
    Tobin, S. J.
    Zer, C.
    Avery, K. N.
    Williams, J. C.
    Jovanovic-Talisman, T.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
  • [42] MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
    Lisa Svartdal Normann
    Miriam Ragle Aure
    Suvi-Katri Leivonen
    Mads Haugland Haugen
    Vesa Hongisto
    Vessela N. Kristensen
    Gunhild Mari Mælandsmo
    Kristine Kleivi Sahlberg
    Scientific Reports, 11
  • [43] Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer
    Le, Xiao-Feng
    Almeida, Maria I.
    Mao, Weiqun
    Spizzo, Riccardo
    Rossi, Simona
    Nicoloso, Milena S.
    Zhang, Shu
    Wu, Yun
    Calin, George A.
    Bast, Robert C., Jr.
    PLOS ONE, 2012, 7 (07):
  • [44] MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
    Normann, Lisa Svartdal
    Aure, Miriam Ragle
    Leivonen, Suvi-Katri
    Haugen, Mads Haugland
    Hongisto, Vesa
    Kristensen, Vessela N.
    Maelandsmo, Gunhild Mari
    Sahlberg, Kristine Kleivi
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [45] MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
    Svartdal, L. G.
    Aure, M. R.
    Leivonen, S-K.
    Haugen, M. H.
    Hongisto, V.
    Kristensen, V. N.
    Maelandsmo, G. M.
    Sahlberg, K. K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [46] Development and Initial Characterization of the First 18F-CXCR2-Targeting Radiotracer for PET Imaging of Neutrophils
    Spatz, Philipp
    Chen, Xinyu
    Reichau, Kora
    Huber, Max E.
    Muehlig, Saskia
    Matsusaka, Yohji
    Schiedel, Matthias
    Higuchi, Takahiro
    Decker, Michael
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (08) : 6327 - 6343
  • [47] Evaluation of the Anti-HER2 C6.5 Diabody as a PET Radiotracer to Monitor HER2 status and Predict Response to Trastuzumab Treatment
    Reddy, Smitha
    Shaller, Calvin C.
    Doss, Mohan
    Shchaveleva, Irina
    Marks, James D.
    Yu, Jian Q.
    Robinson, Matthew K.
    CLINICAL CANCER RESEARCH, 2011, 17 (06) : 1509 - 1520
  • [48] Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
    Hackshaw, Michelle D.
    Danysh, Heather E.
    Singh, Jasmeet
    Ritchey, Mary E.
    Ladner, Amy
    Taitt, Corina
    Camidge, D. Ross
    Iwata, Hiroji
    Powell, Charles A.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (01) : 23 - 39
  • [49] Development of a non-radiometric method for measuring the arterial input function of a 11C-labeled PET radiotracer
    Shetty, H. Umesha
    Zoghbi, Sami S.
    Morse, Cheryl L.
    Kowalski, Aneta
    Hirvonen, Jussi
    Innis, Robert B.
    Pike, Victor W.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [50] [11C]Carbon monoxide: advances in production and application to PET radiotracer development over the past 15 years
    Taddei, Carlotta
    Pike, Victor W.
    EJNMMI RADIOPHARMACY AND CHEMISTRY, 2019, 4 (01)
12345